Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Amplia Therapeutics Ltd. ( (AU:ATX) ) has provided an update.
Amplia Therapeutics Limited has made significant progress in its ACCENT Phase 2a trial for pancreatic cancer, recruiting half of the required patients and achieving a total of nine confirmed partial responses, which surpass the historical benchmark for similar studies. The company has also initiated a research collaboration with Next&Bio to explore the effectiveness of its FAK inhibitors in combination with kRas inhibitors for treating pancreatic and other cancers. Amplia’s financial position has strengthened with a successful capital raise to support ongoing trials and further development of its lead compound, narmafotinib.
More about Amplia Therapeutics Ltd.
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company focuses on treating fibrotic cancers, particularly pancreatic cancer, and also targets chronic diseases such as idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: 10.0%
Average Trading Volume: 28,267
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $20.31M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.
